Victory Capital Management Inc. Has $287,000 Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Victory Capital Management Inc. decreased its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 43.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,674 shares of the life sciences company’s stock after selling 9,832 shares during the period. Victory Capital Management Inc.’s holdings in Integra LifeSciences were worth $287,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of IART. KBC Group NV grew its stake in shares of Integra LifeSciences by 65.2% during the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after purchasing an additional 1,120 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after purchasing an additional 2,800 shares during the last quarter. Nordea Investment Management AB grew its stake in shares of Integra LifeSciences by 4.1% during the fourth quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company’s stock valued at $2,919,000 after purchasing an additional 5,032 shares during the last quarter. Choreo LLC grew its stake in shares of Integra LifeSciences by 29.9% during the fourth quarter. Choreo LLC now owns 22,274 shares of the life sciences company’s stock valued at $500,000 after purchasing an additional 5,123 shares during the last quarter. Finally, Empowered Funds LLC bought a new stake in shares of Integra LifeSciences during the fourth quarter valued at approximately $180,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Analysts Set New Price Targets

Separately, Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, Integra LifeSciences presently has a consensus rating of “Hold” and an average price target of $23.00.

Integra LifeSciences Price Performance

Shares of IART stock opened at $22.49 on Friday. Integra LifeSciences Holdings Co. has a 52-week low of $16.81 and a 52-week high of $35.49. The stock has a market cap of $1.74 billion, a PE ratio of -249.86, a PEG ratio of 0.73 and a beta of 1.23. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The firm’s 50 day moving average price is $23.85 and its two-hundred day moving average price is $22.05.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. The company had revenue of $442.65 million for the quarter, compared to analysts’ expectations of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period last year, the firm posted $0.89 earnings per share. As a group, analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.